Novavax to deliver 60 million doses of COVID-19 vaccine candidate to UK for trial

17Views

August 14, 2020

U.S. drug developer Novavax Inc said on Friday the UK would buy 60 million doses of its coronavirus vaccine candidate, NVX-CoV2373, for a phase 3 clinical trial in the country.

The company and the UK government will collaborate for the trial to assess the efficacy of the vaccine in the UK population, Novavax said in a statement, but did not disclose any financial details of the agreement.

The trial will be a study in about 9,000 adults between 18 years and 85 years of age.

Novavax would partner with Fujifilm Diosynth Biotechnologies for manufacturing the antigen component of its COVID-19 vaccine candidate in the UK, it added.

The company is also gearing up to deliver 100 million doses to the United States by January after it was awarded $1.6 billion to cover testing and manufacturing of its potential vaccine in the country.

Novavax has received $2 billion in funding so far for its coronavirus vaccine, including $384 million from the Coalition for Epidemic Preparedness Innovations (CEPI).

Novavax will supply the NVX-CoV2373 doses to the UK beginning as early as the first quarter of 2021, while phase 3 trial is expected to begin in the third quarter of this year, the company said.

The Fujifilm Diosynth Biotechnologies site in the UK is expected to produce about 180 million doses annually, it added.

The United States and United Kingdom are leading a rush to strike deals with drugmakers to reserve supplies of experimental coronavirus vaccines, as the race to develop a safe and effective vaccine reaches the final stages of testing.

There are currently no approved vaccines for COVID-19, with over 25 candidates being studied in humans.

Also Watch

Sushant Death Probe: Maharashtra Govt Opposes CBI Probe Says It Violates Federal Structure

In an early-stage trial, Novavax’s vaccine candidate, NVX-CoV2373, has produced higher levels of antibodies in healthy volunteers after two doses than those found in recovered COVID-19 patients and the vaccine was “well tolerated” overall.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Array
(
[videos] => Array
(
[0] => Array
(
[id] => 5f361bf5a07a3a25bbc1b7c4
[youtube_id] => f1R2wr1nEzE
Novavax to deliver 60 million doses of COVID-19 vaccine candidate to UK for trial => Sushant Death Probe: Maharashtra Govt Opposes CBI Probe Says It Violates Federal Structure
)

[1] => Array
(
[id] => 5f361691a07a3a25bbc1b6b6
[youtube_id] => ue9sI9UGU3I
Novavax to deliver 60 million doses of COVID-19 vaccine candidate to UK for trial => Chinese Hawala Racket: CAIT Writes To Finance Minister Demanding ED Probe Into The Case
)

)

[query] => https://pubstack.nw18.com/pubsync/v1/api/videos/recommended?source=n18english&channels=5d95e6c378c2f2492e2148a2,5d95e6c278c2f2492e214884,5d96f74de3f5f312274ca307&categories=5d95e6d7340a9e4981b2e10a&publish_min=2020-08-11T10:45:03.000Z&publish_max=2020-08-14T10:45:03.000Z&sort_by=date-relevance&order_by=0&limit=2
)

Novavax to deliver 60 million doses of COVID-19 vaccine candidate to UK for trial

Also Watch

Speak Your Mind

LEAVE A REPLY Cancel reply

Get in Touch

Recommend for You

Oh hi there It’s nice to meet you.

Subscribe and receive our weekly newsletter packed with awesome articles that really matters to you!

You might also like

EDITOR PICKS

POPULAR POSTS

POPULAR CATEGORY

About Us

Follow Us

Support Us & Be a Patreon

Add QNewsHub to your Homescreen!

Oh hi there
It’s nice to meet you.